The publication of positive phase III trial results in a reputable journal like the New England Journal of Medicine is likely to boost investor confidence in Roche's Gazyva/Gazyvaro. The demonstrated superiority over standard therapy in treating lupus nephritis could lead to increased adoption and sales, positively impacting Roche's stock price.